Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D D Von Hoff

Showing results (1-10 of 455) with videos related to

Pageof 46
Sort By:
Seminars in Oncology|October 1, 1996
Gemcitabine: a case study for clinical benefitD D Von Hoff
Seminars in Oncology|October 1, 1991
In vitro data supporting interferon plus cytotoxic agent combinationsD D Von Hoff
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1994
MGBG: teaching an old drug new tricksD D Von Hoff
Seminars in Oncology|December 1, 1984
Use of daunorubicin in patients with solid tumorsD D Von Hoff
Cancer Investigation|January 1, 1995
New agent development for women with breast cancerD D Von Hoff
Seminars in Oncology|October 24, 1998
Promising new agents for treatment of patients with colorectal cancerD D Von Hoff
Seminars in Oncology|October 1, 1990
Phase I clinical trials with fludarabine phosphateD D Von Hoff
Cancer Metastasis Reviews|December 1, 1988
Human tumor cloning assays: applications in clinical oncology and new antineoplastic agent developmentD D von Hoff
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award LectureD D Von Hoff
Seminars in Oncology|August 1, 1997
The taxoids: same roots, different drugsD D Von Hoff
Pageof 46

Showing results (1-10 of 455) with videos related to

Sort By:
Pageof 46
Seminars in Oncology|October 1, 1996
Gemcitabine: a case study for clinical benefitD D Von Hoff
Seminars in Oncology|October 1, 1991
In vitro data supporting interferon plus cytotoxic agent combinationsD D Von Hoff
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1994
MGBG: teaching an old drug new tricksD D Von Hoff
Seminars in Oncology|December 1, 1984
Use of daunorubicin in patients with solid tumorsD D Von Hoff
Cancer Investigation|January 1, 1995
New agent development for women with breast cancerD D Von Hoff
Seminars in Oncology|October 24, 1998
Promising new agents for treatment of patients with colorectal cancerD D Von Hoff
Seminars in Oncology|October 1, 1990
Phase I clinical trials with fludarabine phosphateD D Von Hoff
Cancer Metastasis Reviews|December 1, 1988
Human tumor cloning assays: applications in clinical oncology and new antineoplastic agent developmentD D von Hoff
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award LectureD D Von Hoff
Seminars in Oncology|August 1, 1997
The taxoids: same roots, different drugsD D Von Hoff
Pageof 46